Bayer and Regeneron's AMD treatment shows visual improvement at one year
This article was originally published in Scrip
Executive Summary
Bayerand Regeneron Pharmaceuticals' investigational wet age-related macular degeneration (AMD) treatment VEGF Trap-Eye (aflibercept) is associated with improvements in visual acuity for up to a year, new Phase II data show.